Inogen appoints Andy Reding as COO effective July 6, 2026

Inogen Inc

Andy Reding appointed to newly created COO role, effective July 6, 2026.
Reding previously Chief Commercial Officer at Viant Medical and VP/GM at Hillrom Respiratory Health.
Compensation: $500k base salary, 70% target bonus, $100k sign-on bonus, 130,000 RSUs vesting over 3 years.
Severance: 12 months base salary if terminated without cause outside change of control; 24 months within change of control period.
Inducement equity award granted under Nasdaq Rule 5635(c)(4).

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Andrew (Andy) Reding

Executive Vice President, Chief Operating Officer

INGN · Inogen Inc

Effective: 2026-07-06
Filed: July 1, 2026, 4:09 PM ET

appointed Andrew (Andy) Reding to serve as Executive Vice President, Chief Operating Officer (“COO”) of the Company, effective July 6, 2026.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Andrew (Andy) Reding was appointed as Executive Vice President, Chief Operating Officer at Inogen Inc.

Action: appointed
Role: Executive Vice President, Chief Operating Officer

Exact text from the filing

appointed Andrew (Andy) Reding to serve as Executive Vice President, Chief Operating Officer (“COO”) of the Company, effective July 6, 2026.

View on SEC.gov

Inogen Inc filing history →

Source: SEC EDGAR

accession 0001294133-26-000025

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.